for a Brighter Tomorrow
JOIN MAILING LIST
PRESENTATION
PIPELINE
INVESTORS
ABOUT US
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.
Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.
PRESS RELEASES
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
1,125 patients combined in both studies Efficacy data available after the 6-month [...]
Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
Oral Presentation on Oral Insulin Effect on Diabetes and Poster Presentation [...]